VistaGen Therapeutics
VTGN
54 hedge funds and large institutions have $44.9M invested in VistaGen Therapeutics in 2024 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 19 increasing their positions, 10 reducing their positions, and 8 closing their positions.
90% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 10
88% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 8
15% more funds holding
Funds holding: 47 → 54 (+7)
0.65% less ownership
Funds ownership: 56.4% → 55.75% (-0.65%)
1% less capital invested
Capital invested by funds: $45.3M → $44.9M (-$422K)
81% less call options, than puts
Call options by funds: $315K | Put options by funds: $1.62M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$2.17M |
| 2 |
SC
Stempoint Capital
New York
|
+$1.36M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$1.31M |
| 4 |
AC
Almitas Capital
Santa Monica,
California
|
+$717K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$639K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$6.02M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.03M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$906K |
| 4 |
Renaissance Technologies
New York
|
-$301K |
| 5 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$117K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
51
Tower Research Capital (TRC)
New York
| $658 | -$5.73K | -2,036 | -90% |
|
|
SIC
52
SJS Investment Consulting
Sylvania,
Ohio
| $295 | – | – | – |
|
|
FG
53
Fairman Group
Chesterbrook,
Pennsylvania
| $86 | – | – | – |
|
54
Citigroup
New York
| $9 | -$3.45K | -1,226 | -100% |
|
|
BI
55
BVF Inc
San Francisco,
California
| – | -$6.02M | -2,000,000 | Closed |
|
|
GPP
56
Great Point Partners
Greenwich,
Connecticut
| – | -$2.03M | -674,075 | Closed |
|
|
57
Citadel Advisors
Miami,
Florida
| – | -$906K | -321,885 | Closed |
|
|
VU
58
Valence8 US
Cambridge,
Massachusetts
| – | -$103K | -34,376 | Closed |
|
|
VF
59
Virtu Financial
New York
| – | -$61K | -20,210 | Closed |
|
60
Jane Street
New York
| – | -$59.2K | -19,659 | Closed |
|
|
FFA
61
Farther Finance Advisors
San Francisco,
California
| – | -$244 | -81 | Closed |
|
62
Fidelity Investments
Boston,
Massachusetts
| – | -$75 | -25 | Closed |
|
VTGN Hedge Fund Activity: Q4 2024 in Review
54 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q4 2024, worth a combined $44.9M — down 0.93% from $45.3M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new VTGN positions and 8 closed out — a net gain of 7 holders — while 19 added to existing stakes and 10 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $2.17M. The largest seller was BVF Inc, exiting entirely with an estimated $6.02M sold.
- 54 institutional investors held VistaGen Therapeutics (VTGN) as of Q4 2024, up from 47 in Q3 2024.
- Funds reported $44.9M of VistaGen Therapeutics stock for Q4 2024, down 0.93% quarter-over-quarter.
- 15 funds opened new VistaGen Therapeutics positions in Q4 2024 and 8 closed out, a net change of +7 holders.
- The largest VistaGen Therapeutics buyer in Q4 2024 was JP Morgan Chase, an estimated $2.17M added.
- The largest VistaGen Therapeutics seller in Q4 2024 was BVF Inc, an estimated $6.02M sold.
Based on aggregated 13F filings for Q4 2024.